CliffBio
biologic

Andembry

garadacimab-gxii

Loss of exclusivityJune 2037projected — 12-year biologic exclusivity estimate
CompanyCSL Behring →See this company's full patent-cliff portfolio

Drug detail

Brand nameAndembry
Active ingredientgaradacimab-gxii
Strength200MG/1.2ML (167MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2025
Marketing statusRx

More from CSL Behring

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.